Gennex Laboratories share news, announcements and annual reports
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹8.96.
30 Oct: open ₹8.91, high ₹9.12, low ₹7.70
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹195 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 10.60
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 13,21,688
Gennex Laboratories share news and announcements
553 announcements, routine notices left out, newest first. Page 10 of 12.
Jul 2017
27 Jul · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2017
21 Jul · Shareholding for the Period Ended June 30, 2017
Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click ....
May 2017
Apr 2017
21 Apr · Sub: Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
21 Apr · Statement Of Investor Complaints Redressal Mechanism Under Regulation
21 Apr · Shareholding for the Period Ended March 31, 2017
Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click ....7 Apr · Legal
7 Apr · Legal
Exchange has sought clarification from Gennex Laboratories Ltd on April 07, 2017, with reference to increase in Price. The reply is awaited.
Feb 2017
Jan 2017
22 Jan · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
20 Jan · Shareholding for the Period Ended December 31, 2016
Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click ....
Nov 2016
Oct 2016
20 Oct · Shareholding for the Period Ended September 30, 2016
Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click ....14 Oct · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Sep 2016
2 Sep · Meeting
Aug 2016
22 Aug · Board Meeting on August 29, 2016
Jul 2016
27 Jul · Shareholding for the Period Ended June 30, 2016
Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click ....
May 2016
20 May · Board meeting
Meeting of Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider and approve the audited financial result ....
Apr 2016
21 Apr · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
19 Apr · Shareholding for the Period Ended March 31, 2016
Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click ....
Feb 2016
13 Feb · Limited Review Report for December 31, 2015
Jan 2016
27 Jan · Shareholding for the Period Ended December 31, 2015
Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click ....27 Jan · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Nov 2015
Oct 2015
21 Oct · Shareholding Pattern for September 30, 2015
7 Oct · Legal
7 Oct · Legal
Exchange has sought clarification from Gennex Laboratories Ltd on October 7, 2015, with reference to increase in Price. The reply is awaited.
Sep 2015
Aug 2015
25 Aug · Corporate action
Register of Members & Share Transfer Books of the Company will remain closed from September 26, 2015 to September 30, 2015 (both days inclusive) ....25 Aug · Meeting
Jul 2015
16 Jul · Shareholding Pattern For June 30, 2015
Jun 2015
2 Jun · Management
Apr 2015
10 Apr · Shareholding Pattern For March 31, 2015